BCRX
Price
$8.64
Change
-$0.07 (-0.80%)
Updated
Jul 16, 12:55 PM (EDT)
Capitalization
1.82B
15 days until earnings call
LXRX
Price
$1.19
Change
+$0.03 (+2.61%)
Updated
Jul 16, 11:32 AM (EDT)
Capitalization
417.65M
15 days until earnings call
Interact to see
Advertisement

BCRX vs LXRX

Header iconBCRX vs LXRX Comparison
Open Charts BCRX vs LXRXBanner chart's image
BioCryst Pharmaceuticals
Price$8.64
Change-$0.07 (-0.80%)
Volume$3.6K
Capitalization1.82B
Lexicon Pharmaceuticals
Price$1.19
Change+$0.03 (+2.61%)
Volume$20.48K
Capitalization417.65M
BCRX vs LXRX Comparison Chart in %
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. LXRX commentary
Jul 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and LXRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 16, 2025
Stock price -- (BCRX: $8.72 vs. LXRX: $1.15)
Brand notoriety: BCRX: Notable vs. LXRX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 69% vs. LXRX: 77%
Market capitalization -- BCRX: $1.82B vs. LXRX: $417.65M
BCRX [@Biotechnology] is valued at $1.82B. LXRX’s [@Biotechnology] market capitalization is $417.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 0 FA rating(s) are green whileLXRX’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 0 green, 5 red.
  • LXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, LXRX is a better buy in the long-term than BCRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 4 TA indicator(s) are bullish while LXRX’s TA Score has 4 bullish TA indicator(s).

  • BCRX’s TA Score: 4 bullish, 5 bearish.
  • LXRX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, LXRX is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Biotechnology) experienced а -0.80% price change this week, while LXRX (@Biotechnology) price change was +25.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.08%. For the same industry, the average monthly price growth was +9.30%, and the average quarterly price growth was +35.11%.

Reported Earning Dates

BCRX is expected to report earnings on Oct 29, 2025.

LXRX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($1.83B) has a higher market cap than LXRX($418M). LXRX YTD gains are higher at: 55.721 vs. BCRX (15.957). BCRX has higher annual earnings (EBITDA): 47.6M vs. LXRX (-164.27M). BCRX has more cash in the bank: 295M vs. LXRX (195M). LXRX has less debt than BCRX: LXRX (102M) vs BCRX (795M). BCRX has higher revenues than LXRX: BCRX (503M) vs LXRX (31.2M).
BCRXLXRXBCRX / LXRX
Capitalization1.83B418M437%
EBITDA47.6M-164.27M-29%
Gain YTD15.95755.72129%
P/E RatioN/AN/A-
Revenue503M31.2M1,612%
Total Cash295M195M151%
Total Debt795M102M779%
FUNDAMENTALS RATINGS
BCRX vs LXRX: Fundamental Ratings
BCRX
LXRX
OUTLOOK RATING
1..100
5320
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
74100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5135
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (50) in the Biotechnology industry is in the same range as LXRX (50). This means that BCRX’s stock grew similarly to LXRX’s over the last 12 months.

BCRX's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as LXRX (100). This means that BCRX’s stock grew similarly to LXRX’s over the last 12 months.

BCRX's SMR Rating (100) in the Biotechnology industry is in the same range as LXRX (100). This means that BCRX’s stock grew similarly to LXRX’s over the last 12 months.

LXRX's Price Growth Rating (35) in the Biotechnology industry is in the same range as BCRX (51). This means that LXRX’s stock grew similarly to BCRX’s over the last 12 months.

LXRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BCRX (100). This means that LXRX’s stock grew similarly to BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXLXRX
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
79%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DBMG41.58N/A
N/A
DBM Global Inc.
RUSMF32.55N/A
N/A
Russel Metals Inc.
WWNTY32.44N/A
N/A
Want Want China Holdings Ltd
LVMUY110.83-1.30
-1.16%
LVMH-Moet Hennessy Louis Vuitton
EMGDF0.27-0.01
-1.99%
EMINENT GOLD CORP.